Latest InspireMD Inc. Stories

BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- -Strong Conference Presence to Include Presentations/Educational Events Featuring the MGuard(TM) Embolic Protection Stent- - Company to Host Conference Call on Thursday, May 23rd to Review MASTER Data - InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), the leader in embolic protection stents, today announced a...

- More than 18 Million Brazilians have Reimbursable Access to MGuard EPS - BOSTON and TEL AVIV, Israel, May 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced that it received reimbursement approval for the MGuard(TM) Coronary Embolic Protection Stent (EPS) from UNIMED, Brazil's largest private health care insurer. Alan Milinazzo, InspireMD's President and CEO said,...

- Revenue increased 33% over prior year - BOSTON and TEL AVIV, Israel, May 8, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR), a leader in embolic protection stents, today announced financial results for the three month period ended March 31, 2013, the third quarter of its 2013 fiscal year. Revenue for the period increased by 33% over the March 31, 2012 quarter, reflecting the impact of several new marketing initiatives leveraging positive...

BOSTON and TEL-AVIV, Israel, April 23, 2013 /PRNewswire/ -- InspireMD, Inc. (NYSE MKT: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) Embolic Protection Stent (EPS), announced today that on April 19, 2013, the Company received an approval with conditions for its Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA). An approval with conditions indicates that the FDA concurs with the overall trial design and...

Former Covidien Executive, Gwen Bame, Will Focus on Strategic Programs Worldwide TEL AVIV, Israel, April 19, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) said Gwen K. Bame has joined the Company as Vice President of Corporate Development, reporting directly to Alan Milinazzo, President and CEO. "This is a new position created to strengthen our executive team with a clear focus on executing strategic programs and partnerships...

TEL AVIV, Israel, April 16, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the closing of an underwritten public offering of 12.5 million shares of its common stock at a price to the public of $2.00 per share. The Company received net proceeds of approximately $22.6 million, after deducting underwriting discounts and commissions and other offering-related costs. InspireMD granted the underwriters a 30-day option to purchase up to...

TEL AVIV, Israel, April 10, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (NYSE MKT: NSPR) announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.00 per share. The net proceeds to the Company from this offering are expected to be approximately $22.6 million, after deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on...

TEL-AVIV, Israel, March 15, 2013 /PRNewswire/ -- InspireMD's Carotid Embolic Protection Stent, based on InspireMD's proprietary MicroNet[TM] mesh technology, is designed to provide procedural and post-procedural distal embolic protection in Carotid Artery Stenting(CAS) procedures and there by reduce risk of stroke events. InspireMD, Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer of the MGuard(TM) Embolic Protection Stent (EPS), announced today that the...

TEL AVIV, Israel, March 7, 2013 /PRNewswire/ -- InspireMD, Inc. (OTC: NSPR) (the "Company" or "InspireMD") filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the resumption of a proposed underwritten public offering. Under the amended registration statement, the Company is offering $30 million worth of its shares of common stock. In addition, InspireMD intends to grant the underwriters a 30-day option...

TEL AVIV, Israel, February 11, 2013 /PRNewswire/ -- InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD) announced that Michael Berman joined its board of directors. Mr. Berman previously served as a Senior Vice President of Boston Scientific Corp., Group President of its cardiology businesses, and a member of the Executive Committee. Since leaving Boston Scientific, Mr. Berman co-founded or was a founding director of seven medical technology companies,...